Amicus Therapeutics (FOLD) Stock Forecast & Price Target

Amicus Therapeutics Inc. has demonstrated a robust growth trajectory, with Galafold achieving approximately 18% year-over-year sales growth in 2024, amounting to $458 million, supported by the largest increase in new patient demand since its launch. The company anticipates continued growth for Galafold, projecting sales to rise by 10-15% in constant exchange rates for 2025, which aligns with their estimation of $504 million for that period. Additionally, Amicus is capturing significant market share for its Pompe disease therapy from competitors, driven by stronger-than-expected sales and improvements in patient identification through innovative AI initiatives.

Amicus Therapeutics Inc. has experienced an 18% year-over-year growth in FY:24 Galafold sales, which totaled approximately $458 million, though projections indicate that growth may slow down in FY:25 with an estimated sales figure of $504 million. The company anticipates a slight negative impact of $5 million to $15 million on total revenues due to current exchange rates and a potential reduction in the patient pool due to increased treatment, which could lead to decreased revenues. Furthermore, the need for additional clinical trials and more data, stemming from a conservative FDA stance, could result in significant delays in market approval, which poses additional risks to future financial performance.